3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Melanoma
106
Carcinoma, Non-Small-Cell Lung
34
Carcinoma, Renal Cell
23
Prostatic Neoplasms
17
Neoplasms
15
Brain Neoplasms
15
Neoplasm Metastasis
14
Lung Neoplasms
12
Breast Neoplasms
11
Uveal Melanoma
10
Pancreatic Neoplasms
10
Sarcoma
9
Small Cell Lung Carcinoma
7
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Skin Neoplasms
5
Ovarian Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Neuroendocrine Tumors
4
Mesothelioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Microsatellite Unstable Colorectal Cancer
×
Ipilimumab
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA